Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the...

Related Keywords

,Mahesh Patel ,Prnewswire Lipocine Inc ,Drug Administration ,Lipocine Inc ,Nasdaq ,Dosing Validation ,New Oral Testosterone ,Male Hypogonadism ,Chief Executive Officer ,